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ABSTRACT
The importance of the estrogen receptor (ER)
in breast cancer (BCa) development makes it a
prominent target for therapy. Current treatments,
however, have limited effectiveness, and hence the
definition of new therapeutic targets is vital. The
ER is a member of the nuclear hormone receptor
superfamily of transcription factors that requires
co-regulator proteins for complete regulation.
Emerging evidence has implicated a small number
of histone methyltransferase (HMT) and histone
demethylase (HDM) enzymes as regulators of ER
signalling, including the histone H3 lysine 9 tri-/di-
methyl HDM enzyme KDM4B. Two recent independ-
ent reports have demonstrated that KDM4B is
required for ER-mediated transcription and deple-
tion of the enzyme attenuates BCa growth in vitro
and in vivo. Here we show that KDM4B has an over-
arching regulatory role in the ER signalling cascade
by controlling expression of the ER and FOXA1
genes, two critical components for maintenance of
the estrogen-dependent phenotype. KDM4B inter-
acts with the transcription factor GATA-3 in BCa
cell lines and directly co-activates GATA-3 activity
in reporter-based experiments. Moreover, we reveal
that KDM4B recruitment and demethylation of re-
pressive H3K9me3 marks within upstream regula-
tory regions of the ER gene permits binding of
GATA-3 to drive receptor expression. Ultimately,
our findings confirm the importance of KDM4B
within the ER signalling cascade and as a potential
therapeutic target for BCa treatment.
INTRODUCTION
Breast cancer (BCa) is the most prevalent malignancy in
women, and almost two-thirds of newly diagnosed BCas
express the estrogen receptor (ER), which remains the
primary target for disease therapy. By preventing
binding of the ER to its activating hormone estrogen,
endocrine therapy, via use of tamoxifen, is responsible
for decreasing BCa incidence by 50% (1). Most
malignancies, however, become refractory to treatment
and progress as a consequence of ill-deﬁned molecular
events that enable ER function in the absence of bound
hormone (2).
The ER is a member of the nuclear hormone receptor
superfamily of transcription factors that regulate genes
involved in breast epithelial cell division and transform-
ation (3). Pioneer factors, such as FOXA1 and GATA-3,
facilitate loading of the receptor onto cis-acting enhancer
elements of target genes and permit ordered recruitment of
numerous distinct co-regulator families, which act to
regulate the estrogenic transcriptional response (4).
Importantly, several lines of evidence suggest imbalance
in the relative levels of these co-regulators is involved in
the development of BCa. For example, overexpression of
the histone acetyltransferase enzyme AIB1 has been
reported in 10% of breast tumours (5), while ﬂux to
co-repressor proteins SMRT and N-CoR levels has been
suggested to be causative for tamoxifen resistance (6,7).
Although our present understanding is limited,
emerging evidence implicates an important role for
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enzymes that regulate reversible histone lysine methylation
in ER signalling and BCa (8). Histone lysine methylation
is catalysed by the large family of SET domain-containing
histone methyltransferase (HMT) enzymes that is reversed
by the activity of Jumonji (Jmj) and KDM1 histone
demethylase (HDM) enzymes. Discriminate mono-, di-
and tri-methylation and respective demethylation of
lysines within histones H3 and H4 encompassing euchro-
matic domains acts as a genome-wide epigenetic switch
that can either activate or repress transcription (9,10).
For example, tri-methylation of histone H3 lysine 4
(H3K4me3) is generally associated with transcriptionally
active loci, while tri-methylation of histone H3 lysine 9
(H3K9me3) is generally associated with transcriptionally
silenced, heterochromatic regions. The demonstration
that the histone H3 lysine 27 HMT enzyme EZH2
promotes anchorage-independent growth of the H16N2
BCa cell line (11), and that both EZH2 (12) and the
HDM KDM1A (13) are overexpressed in BCa and
up-regulate the transcriptional activity of the ER (8)
suggest a role for aberrant histone methylation in breast
malignancy.
More recently, two separate reports have suggested that
the H3K9me3/me2-speciﬁc demethylase enzyme KDM4B
is an ER co-regulator by demonstrating that depletion of
the enzyme reduces both receptor-mediated transcription
and growth of BCa cells in vitro and in vivo (14,15). In
addition, the ﬁnding that KDM4B is an ER-responsive
gene (16) suggested the existence of a positive-acting regu-
latory loop between the two proteins in which estrogen-
dependent elevation of KDM4B feeds forward to further
potentiate ER function and up-regulate the estrogenic
response in BCa cells.
Consistent with these ﬁndings, from an siRNA library
screen, we identiﬁed KDM4B as a regulator of the ER
signalling cascade and demonstrated that it is recruited
to cis-regulatory elements of estrogen-dependent genes.
Furthermore, KDM4B depletion markedly reduced ER-
target gene expression in several BCa cell lines, including
MCF-7, T47D and BT-474. Importantly, investigating the
role of KDM4B in the receptor signalling cascade further,
we show for the ﬁrst time that the demethylase is required
for ER gene expression via co-activation of GATA-3, an
important regulator of ER transcription (17). KDM4B is
recruited to both promoter and enhancer elements of the
ER gene, and depletion of the enzyme in BCa cells elevates
H3K9 methylation and attenuates GATA-3 association at
these sites, thus reducing receptor expression. Our data
highlight a novel role for KDM4B in the ER signalling
cascade and demonstrates a cross-regulatory network
involving KDM4B, ER and GATA-3 that is required
for ER gene expression. Lastly, we ﬁnd that KDM4B
also interacts with and regulates FOXA1 expression in
BCa cells, indicating an additional means of regulating
the activity of the ER. In all, our ﬁndings support the
hypothesis that by regulating ER gene transcription,
pioneer factor activity and facilitating estrogen-dependent
gene expression, KDM4B is a master regulator of receptor
signalling and conﬁrms this demethylase as a potentially
important target in BCa therapy.
MATERIALS AND METHODS
Plasmids and antibodies
The following plasmids have been previously described:
pCMV-ER, MUC1-responsive reporter (kind gift from
Prof. Vincent Giguere, McGill University) (18), pCMV-
GATA-3 (kind gift from Dr Jason Carroll, Cambridge
Research Institute, UK) and pCMV-HA-KDM4B and
pCMV-HA-KDM4BH189G/E191Q (kind gift from Dr Peter
Staller, BRIC, Denmark) (19). Antibodies for ER (D-20)
and GATA-3 (HG3-31) were purchased from Santa Cruz
Biotechnology, KDM4B (A301-478A) from Bethyl
Laboratories and FOXA1 (Ab 23738) from Abcam.
Antibodies to histone methylation/acetylation marks
have been previously described (20). To generate pGL3-
Enh1 and pGL3-Enh2 reporters, we ampliﬁed 500 bp
ER gene Enh1 and Enh2 fragments from MCF-7 DNA
with primers containing Xho 1 and Hind III restriction
sites (see Supplementary Table S1), digested with
indicated enzymes and ligated directionally into pGL3-
basic (Promega).
Cell culture and DNA transfection
Cell culture and DNA transfection were performed as
described previously (21). MCF-7, T47D and BT-474
cells were maintained in RPMI-1640 media containing
10% foetal calf serum (FCS) (Sigma). The estrogen-inde-
pendent MCF-7 (EI-MCF-7) cell line was generated by
continuous culturing of MCF-7 cells in phenol red–free
RPMI supplemented with 10% steroid-depleted FCS
(Hyclone) for 6 months before characterization. For
reporter assays, 1 104 MCF-7 cells were routinely
plated per well in 24-well microtitre plates (Corning).
After 24 h, the cells were transfected for 48 h using LT-1
reagent (Mirus Bio) according to the manufacturer’s rec-
ommendations and were subsequently harvested and
assayed for luciferase and b-galactosidase activity as
described previously (22). For estrogenic stimulation or
4-hydroxytamoxifen (Tam) treatment experiments, cells
were grown in phenol red–free RPMI-1640 media supple-
mented with 10% serum-stripped FCS (Hyclone) be-
fore transfection as above. Either 8 or 24 h before
harvesting for mRNA extraction [as described in (20)]
or luciferase assays, respectively, cells were treated with
or without 10 nM b-estradiol (E2) (Sigma) or 1 mM
4-hydroxytamoxifen (Sigma). Unless indicated, quantita-
tive polymerase chain reaction (PCR) analysis data of ER
and ER-target gene mRNA expression [performed as
described in (20); primers for each are shown in
Supplementary Table S1] and luciferase assay data repre-
sents an average of three repeats± standard error
(*denotes P< 0.05). For western blot analysis, parallel ex-
periments to those described above were harvested in
sodium dodecyl sulphate (SDS)-sample buffer and
subject to polyacrylamide gel electrophoresis (SDS-
PAGE) before immunoblotting with speciﬁc antibodies
[as described in (23)]. Cycloheximide time-course experi-
ments were conducted as described in (20). Proliferation
assays using WST-1 (Roche) were performed as described
in (20), and BrdU incorporation assays were performed
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according to the manufacturer’s recommendations
(Roche). BCa cells were pretreated for 3 h with a ﬁnal
concentration of 1 mM fulvestrant (Sigma) before E2
stimulation for an additional 45min before subsequent
gene expression or chromatin immunoprecipitation
(ChIP) analysis.
siRNA transfection
All siRNAs used in the study were purchased from Sigma,
and sequences are shown in Supplementary Table S2. To
rule out off-target effects of KDM4B and GATA-3
knock-down, MCF-7, T47D and BT-474 BCa cell lines
were transfected with four KDM4B siRNAs [labelled
siKDM4B (A)–(D)] either individually or as a pool con-
sisting of siKDM4B (A)/(B)/(C), or two GATA-3 [labelled
siGATA-3 (1)/(2)] oligonucleotides using Lipofectamine
RNAiMax (Invitrogen) according to manufacturer’s rec-
ommendations at a ﬁnal concentration of 25 nM and as
described (20). Unless otherwise stated, KDM4B knock-
down experiments were primarily performed with
siKDM4B (C) oligonucleotides. The initial siRNA
library screen was conducted by reverse transfecting
MCF-7 cells grown in phenol red–free steroid-depleted
media for 72 h in the presence and absence of 10 nM E2
with a pool of three individual siRNAs per 50 HMT and
27 HDM enzymes studied. mRNA was extracted using
Trizol and cDNA generated and analysed by quantitative
PCR, as described (20). Additional transcriptional valid-
ation experiments were performed using individual or
pooled siKDM4B (A)/(B)/(C) compared with cells
depleted of ER or pS2 (see Supplementary Table S2 for
sequences).
For RNAi rescue experiments, ﬁve silent mutations
were introduced into the KDM4B siRNA (C) target
sequence within pCMV-HA-KDM4B by two rounds of
site-directed mutagenesis using the following primer com-
binations: KDM4B-CS1 F: 50-TGC GAC GCC TTC
CTG CGA CAC AAA ATG ACC CTC ATC TGC-30,
KDM4B-CS1 R: 50- GCA GAT GAG GGT CAT TTT
GTG TCG CAGGAA GGC GTC GCA-30 and KDM4B-
CS2 F: 50-CTG CGA CAC AAA ATG ACA CTG ATC
TCG CCC ATC-30, KDM4B-CS2 R: 50-GAT GGG CGA
GAT CAG TGT CAT TTT GTG TCG CAG-30, to
permit expression of ectopic enzyme in cells depleted of
endogenous KDM4B. The resultant ‘codon-switch (CS)’
pCMV-HA-CS-KDM4B vector or control plasmid was
co-transfected with either scrambled (Scr) or KDM4B
(C) siRNAs for 48 h before respective western blot and
quantitative PCR analyses of ER protein and mRNA
levels.
Immunoprecipitation, ChIP and chromatin fractionation
To investigate endogenous KDM4B-ER and KDM4B-
GATA-3 interactions in MCF-7 and T47D cells,
immunoprecipitations (IPs) were performed using
KDM4B, ER and GATA-3 antibodies using a previously
described protocol (21). To assess ectopically expressed
KDM4B-ER and KDM4B-FOXA1 interactions, pCMV-
HA-KDM4B was transiently transfected into MCF-7
cells, and after 48 h, resultant ER or FOXA1
immunoprecipitates were subject to western blotting
using a KDM4B antibody.
ChIP was performed essentially as described (24).
Brieﬂy, 2 106 MCF-7 or T47D cells were cultured in
steroid-depleted media for a total of 72 h including a
10 nM E2 treatment for the last 45 and 180min of incu-
bation. Cells were ﬁxed in 1% formaldehyde for 10min
and glycine treated for 5min before cell scraping and cen-
trifugation. Resultant pellets were washed in phosphate
buffered saline (PBS) and resuspended in LB1 solution
(50mM HEPES-KOH, pH 7.5; 140mM NaCl; 1mM
EDTA; 10% glycerol; 0.5% NP-40; 0.25% Triton-X-
100) for 10min with gentle agitation at 4C. Samples
were centrifuged at 1500g for 5min before lysis in 10ml
LB2 buffer (10mM Tris–HCl, pH 8; 200mM NaCl; 1mM
EDTA; 0.5mM EGTA) at 4C for 10min with gentle
agitation. Lysates were centrifuged as before and result-
ant pellets resuspended in 0.5ml LB3 buffer (10mM Tris–
HCl, pH 8; 100mM NaCl; 1mM EDTA; 0.5mM EGTA;
0.1% Na-Deoxycholate; 0.5% N-lauroylsarcosine).
Samples were subject to a preoptimized sonication pro-
gramme using a BioruptorTM (Diagenode) incorporating
20 cycles of 30 s on/30 s off at the ‘Hi’ setting and then
centrifuged for 10min at 13 000g. DNA concentration for
each supernatant was measured using a Nanodrop spec-
trometer, and 100 mg chromatin was transferred into a
fresh tube and diluted 5-fold in LB3 buffer containing
1% Triton-X-100. Ten percent of each solution was
taken as input and frozen until the next day. Fifty micro-
litre per sample of Dynabeads conjugated to Protein A
(Invitrogen) was transferred into fresh tubes and blocked
with three washes of PBS containing 0.5% bovine serum
albumin (PBS-BSA) before incubation with 2 mg
antibodies overnight at 4C. Dynabeads were then
washed twice with PBS-BSA to remove any unbound
antibody, and the 50 mg chromatin samples prepared the
previous day were added to the appropriate Dynabead
samples and mixed overnight at 4C. Dynabeads were
subsequently washed six times in RIPA buffer (50mM
HEPES-KOH, pH 7.5; 500mM LiCl; 1mM EDTA; 1%
NP-40; 0.7% Na-Deoxycholate) and once in Tris-buffered
saline (20mM Tris–HCl, pH 7.6; 150mM NaCl) before
incubation for 8 h in 200 ml elution buffer (50mM Tris–
HCl, pH 8; 10mM EDTA) at 65C to elute protein–DNA
complexes and to reverse formaldehyde-induced cross-
links. In addition, input samples taken the previous day
were defrosted and subject to elution/cross-link reversal.
Samples were diluted 1-fold in TE buffer and subject to
proteolytic digestion using 4 ml 20mg/ml proteinase K
(Invitrogen) for 1 h at 55C. DNA was puriﬁed using a
GeneEluteTM genomic DNA miniprep kit (Sigma) and
subject to quantitative PCR using primers speciﬁc to
cis-regulatory elements of the pS2 (TFF1), GREB1 and
ER genes (Supplementary Table S1). Data were pre-
sented as % Input using the following formula: %
Input=100 2^(CT Adjusted Input sampleCT
immunoprecipitated sample) (CT refers to cycle thresh-
old). At least two individual repeats of the entire experi-
ment were conducted and data combined to give an
average % Input (* denotes P< 0.05).
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For Re-ChIP experiments, protein–DNA complexes
from the ﬁrst round of ChIP using a GATA-3 antibody
were eluted in 10mM DTT and diluted 10 in LB3 buffer
and subject to ChIP with either anti-KDM4B or isotype
control antibodies.
To assess the role of KDM4B at cis-regulatory elements
of the ER, pS2, GREB1 and FOXA1 genes, MCF-7,
EI-MCF-7 and T47D cells were transiently transfected
with either Scr or KDM4B siRNAs in steroid-depleted
phenol red–free media and treated with 10 nM E2 for
45min before formaldehyde cross-linking. Antibodies to
KDM4B, GATA-3 and histone methylation and acetyl-
ation marks were used in ChIP as described above.
Chromatin fractionation was performed as described
(25) using 2 106 MCF-7 and T47D cells. Resultant
fraction 3, representing the chromatin-bound fraction of
protein, was subject to SDS-PAGE and immunoblotted
with antibodies as indicated in the ﬁgure legends. Acid
extraction of histone proteins was conducted using the
protocol outlined in (20).
RESULTS
Conﬁrming the involvement of KDM4B in the ER
signalling cascade
To identify HMT and HDM enzymes regulating the ER in
BCa cells, an unbiased siRNA library screen was per-
formed in which each of the human HMT and HDM
enzymes were individually depleted in MCF-7 cells, and
transcriptional activity of the receptor was assessed by
measuring pS2 (TFF1) gene expression (data not shown).
Consistent with two reports describing that the H3K9me3/
me2 demethylase KDM4B as a regulator of ER activity
(14,15), our experiments using several siRNAs [siKDM4B
(A)/(B)/(C)], either individually or pooled, conﬁrmed that
KDM4B depletion down-regulated expression of ER-de-
pendent pS2, progesterone receptor (PgR) (Supplementary
Figures S1A/B) and GREB1 genes (Supplementary Figure
S10A) in response to 10 nM E2. This effect was speciﬁc to
KDM4B, as knock-down of other KDM4 family members
KDM4A, KDM4C and KDM4D did not affect ER-
mediated transcription (data not shown). We next
sought to determine if KDM4B and ER interacted by
probing endogenous ER and KDM4B immunopre-
cipitates from MCF-7 cells with the reciprocal antibodies.
As previously reported (14), we found an interaction
between the two proteins (Figure 1A) and conﬁrmed this
by IP in HEK293T cells ectopically expressing wild-type
KDM4B or demethylase-dead KDM4BH189G/E191Q and
the ER (Figure 1B). Using ChIP in MCF-7 cells, we
show that KDM4B is recruited to ER-responsive
elements within the proximal promoter regions of pS2
and GREB1 genes on E2 stimulation (Figure 1C) that co-
incides with ER recruitment and reduced enrichment of
H3K9me3 marks (Supplementary Figure S2). Depletion
of the enzyme using siKDM4B (C) attenuates ligand-de-
pendent recruitment of the ER (Figure 1D) and up- and
down-regulates respective H3K9me3 (Figure 1E) and
H3K9 acetylation marks (Supplementary Figure S3) at
these loci, consistent with reduced gene expression.
Global histone modiﬁcation marks were also analysed in
cells depleted of KDM4B and the ﬁndings are in-keeping
with previous reports (16), describing effects to H3K9
methylation and acetylation marks (Supplementary
Figure S4). These ﬁndings are consistent with previous
reports and conﬁrm an involvement of KDM4B in the
ER signalling cascade.
KDM4B depletion reduces ER gene expression
Unexpectedly, during the course of our experiments, we
observed that KDM4B depletion by siKDM4B (C)
markedly reduced ER mRNA and protein levels irrespect-
ive of estrogen status in several KDM4B expressing BCa
cell lines, including T47D and both MCF-7 and an
estrogen-dependent variant of this cell line, EI-MCF-7
(see ‘Materials and Methods’ section) (Figure 2,
Supplementary Figure S5–7), a ﬁnding that had not
been reported in the previous studies (14,15). We predict
that this reduction in ER protein is exclusively a conse-
quence of down-regulated ER gene expression and not
enhanced protein turnover, as cycloheximide time-course
experiments in MCF-7 cells ectopically expressing wild-
type KDM4B or KDM4BH189G/E191Q failed to show an
impact on ER stability (Supplementary Figure S8,
middle and right panel). Interestingly, we ﬁnd that en-
dogenous KDM4B has a rapid half-life (<1 h), suggesting
tight cellular control over this enzyme (Supplementary
Figure S8, left panel).
To rule out the possibility that these ﬁndings were off-
target effects of KDM4B depletion by one oligonucleo-
tide, we ﬁrstly used two additional KDM4B-targeting
siRNAs [siKDM4B (A) and (B)] and showed that in
addition to attenuated pS2 expression, ER mRNA and
protein levels were also down-regulated in MCF-7
(Supplementary Figure S9A), BT-474 (Supplementary
Figure S9B) and T47D (data not shown) BCa cell lines.
We next incorporated an additional siRNA as described in
the Shi et al., study (14) [denoted siKDM4B (D)] into ER
expression proﬁling experiments and showed that receptor
levels, as well as pS2 and GREB1 mRNA, were again
depleted in MCF-7 cells grown in steroid-depleted media
supplemented with and without 10 nM E2 (Supplementary
Figure S10A). This ﬁnding was replicated in MCF-7 and
T47D cells grown in serum-containing media
(Supplementary Figure S10B) conﬁrming that reduced
ER expression is a genuine phenotype of KDM4B-
depleted BCa cells. Moreover, growth assays conducted
in both MCF-7 and T47D cells demonstrated reduced
cell proliferation and a subtle, but signiﬁcant, increase in
apoptosis in response to KDM4B knock-down, suggesting
reduced ER levels is likely to be causative for the aberrant
phenotype of the BCa cells (Supplementary Figure S11A
and S11B). Importantly, these data suggest that reduced
ER recruitment to target genes, dys-regulated histone
methylation/acetylation marks and reduced receptor-
mediated transcription evident on KDM4B depletion [as
shown in (14,15), Figure 1 and Supplementary Figures S1
and S3] may be largely ascribed to reduced ER protein
levels and challenges the concept of KDM4B as a bona
ﬁde ER co-activator.
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Figure 1. KDM4B interacts with the ER and is recruited to hormone-responsive genes. (A) MCF-7 cells grown in serum-containing media were
subject to IP using anti-ER, anti-KDM4B or control antibodies before western blot analysis using reciprocal antibodies. (B) HEK293T cells grown in
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were transiently transfected with either Scr control or KDM4B siRNA (siKDM4B) in steroid-depleted media for 72 h with or without 45min 10 nM
E2 stimulation before ChIP with an anti-ER antibody or an anti-H3K9me3 antibody (E), and subsequent analysis at the pS2 and GREB1 EREs.
ChIP data are an average of three independent experiments± standard error (* denotes P< 0.05).
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KDM4B interacts with and co-activates GATA-3
To address how KDM4B controls ER gene expression, we
hypothesized that the enzyme was working through a
known regulator of ER transcription to facilitate up-regu-
lation of receptor levels in BCa cells. The transcription
factor GATA-3 has been well documented to drive expres-
sion of the ER, and as such GATA-3 expression is highly
associated with ER-positive BCa (26,27). Importantly,
GATA-3 has been reported to directly bind the
upstream promoter A (Pro A) and enhancer element 1
(Enh1) and -2 (Enh2) of the ER gene (Figure 4A), and
depletion of the transcription factor in T47D and MCF-
7 cells reduces ER levels, indicating a direct role for
GATA-3 in regulating expression of the receptor [(17),
Figure 3A, Supplementary Figure S12]. The comparable
effects of GATA-3 and KDM4B knock-down on ER ex-
pression suggested that the two proteins may function as
part of the same transcriptional regulatory complex. To
test this, we performed IP of KDM4B in T47D cells and
showed that GATA-3 was speciﬁcally associated with the
demethylase, but not from an immunoprecipitate using an
isotype-control antibody (Figure 3B, left panel). To
conﬁrm the interaction, the reciprocal experiment was per-
formed and we detected KDM4B in GATA-3
immunocomplexes from T47D cells, but again not in the
control experimental arm (Figure 3B, right panel),
indicating that the two proteins are associated in BCa
cells.
To address whether KDM4B is a co-regulator of
GATA-3, we performed reporter experiments in both
T47D and MCF-7 cells, incorporating a GATA-3-respon-
sive MUC1 promoter element upstream from the
luciferase gene (18). As expected, increasing amounts of
GATA-3 increased activity of the reporter by up to 3-fold
(Figure 3C, white bars), and this was markedly increased
by overexpression of KDM4B (Figure 3C, black bars),
indicating that KDM4B co-activates GATA-3 in this
system. Further to this, we cloned 500 bp fragments en-
compassing Enh1 and Enh2 regions of the ER gene into a
luciferase reporter plasmid and measured activity in the
presence and absence of GATA-3 and KDM4B. In MCF-
7 cells, GATA-3 selectively up-regulated the Enh2
reporter that was further elevated by ectopic expression
of KDM4B, conﬁrming the role of the demethylase in co-
activating GATA-3 (Supplementary Figure S13A). This
was further conﬁrmed in ER negative HEK293T cells
(Supplementary Figure 13B).
KDM4B is present at ER gene cis-regulatory elements in
complex with GATA-3
To decipher the mechanism of KDM4B-mediated regula-
tion of GATA-3 activity in a more physiologically relevant
model, we ﬁrstly examined KDM4B recruitment upstream
of the ER gene in the presence and absence of 10 nM E2 by
ChIP in T47D cells. Previous reports have shown that
both GATA-3 and the ER are associated with Enh1,
Enh2 and pro A elements of the upstream regulatory
regions of the ER gene [(17), Figure 4A], and thus we
focused our experiments on these loci. As shown in
Figure 4B (upper panel), KDM4B is associated with all
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Figure 3. KDM4B is a co-regulator of GATA-3. (A) T47D cells grown in serum-containing media were depleted of GATA-3 using two individual
siRNAs [labelled siGATA-3 (1) and (2)] for 48 h before western blot analysis using antibodies to ER, GATA-3 and a-Tubulin. Scr control siRNA
was used as a control. (B) T47D cells grown in serum-containing media were subject to IP using antibodies to either KDM4B, GATA-3 or isotype
control, and interactions using reciprocal antibodies were assessed by western blot analysis. (C) T47D or MCF-7 cells grown as above were
transiently co-transfected with a GATA-3-responsive MUC1 luciferase reporter and KDM4B and increasing amounts of GATA-3 mammalian
expression vectors. After 48 h, cells were harvested for luciferase and b-galactosidase activities, and data are representative of N=3 experi-
ments± standard error (* denotes P< 0.05).
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three cis-regulatory elements in the absence of estrogen,
demonstrating 5-fold enrichment over isotype antibody
control, and remains present after-45 min hormone stimu-
lation. As a control, KDM4B was not associated with a
distal site lacking GATA-3 or ER-binding sites (data not
shown). Importantly, we show that GATA-3 reciprocates
the chromatin-binding kinetics of KDM4B and is present
constitutively at the enhancer and promoter regions of the
ER gene (Figure 4B, middle panel), suggesting the forma-
tion of a complex between the demethylase and GATA-3
at these loci.
To examine this further, we performed re-ChIP experi-
ments in T47D cells in which GATA-3 immunocomplexes
were re-immunoprecipitated with an anti-KDM4B
antibody, and resultant DNA analysed by quantitative
PCR using primer sets to Pro A, Enh1 and Enh2 sites.
As shown in Figure 4C, GATA-3 and KDM4B
are associated in the same complex at these cis-regulatory
elements, conﬁrming the notion that the two pro-
teins function together to regulate ER expression.
Interestingly, the ER is also recruited to the three cis-
regulatory sites of the ER gene in response to estrogen
(Figure 4B, lower panel) and has been shown to be
co-recruited with GATA-3 to these regions (17), suggest-
ing that the enhancement of the GATA-3-KDM4B inter-
action at Enh1 in the presence of hormone (Figure 4C)
may simply be a consequence of elevated GATA-3 recruit-
ment (Figure 4B, middle panel).
Given the presence of the ER at its own promoter and
enhancer regions, one important consideration is whether
reduced expression of the ER gene on depletion of
KDM4B is simply a consequence of attenuated
KDM4B-mediated co-activation of the receptor itself
that may down-regulate ER levels independently of
GATA-3 function. To address this issue, we performed
ER gene expression analysis in both MCF-7 and T47D
cells transiently transfected with KDM4B oligonucleotides
[siKDM4B (C) and (D)] in the presence of estrogen sup-
plemented with and without 1 mM 4-hydroxy-tamoxifen
(Tam). We speculated that if chromatin-bound ER was
an important target of KDM4B-mediated co-activation
activity on the ER gene, there would be reduced
receptor expression in both the Tam-treated and
KDM4B-depleted arms of the experiment. Predictably,
Tam treatment reduced expression of pS2 in both MCF-
7 and T47D cells (Supplementary Figure S14A and S14B,
left panels). Importantly, Tam supplementation alone
failed to appreciably affect ER mRNA levels compared
with control. In contrast, Tam-treated cells depleted of
KDM4B exhibited a marked reduction in ER mRNA
levels equivalent to the ER knock-down control,
indicating that KDM4B is likely functioning through
GATA-3, and not via the receptor, to regulate ER gene
transcription (Supplementary Figure S14A and S14B,
right panels). To further support this hypothesis, we
reasoned that depletion of ER in BCa cells by treatment
with the SERD fulvestrant would not affect recruitment of
KDM4B to ER gene cis-regulatory elements. To ﬁrstly
demonstrate the efﬁcacy of fulvestrant in MCF-7 cells,
we showed that 3-h fulvestrant pretreatment reduced
ER protein levels and attenuated estrogen-induced recruit-
ment of the ER to target genes pS2 and GREB1
(Supplementary Figures S15A and S15B). Importantly,
fulvestrant had no signiﬁcant effect on KDM4B recruit-
ment to the promoter and enhancer elements of the
ER gene (Supplementary Figure S15C). The marginal
reduction in KDM4B promoter association at Enh1 on
fulvestrant treatment is likely a result of reduced
KDM4B levels due to the demethylase being a direct
ER target gene (Supplementary Figure S15B, middle
panel).
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Figure 4. KDM4B is recruited to cis-regulatory elements of the ER
gene. (A) Diagrammatic representation of the position of the
upstream regulatory elements of the ER gene including Pro A,
enhancer 1 (Enh1) and enhancer 2 (Enh2) in respect to the transcrip-
tional start site (+1). (B) T47D cells were grown in steroid-depleted
media for 48 h and treated with 10 nM E2 for 45min before ChIP
analysis using anti-KDM4B, -GATA-3 and –ER antibodies or
isotype control. Recruitment to Pro A, Enh1 and Enh2 was assessed
by quantitative PCR. Data are an average of three independent experi-
ments± standard error. (C) Cells were grown and treated as in (B) and
then subject to a ﬁrst-round ChIP using an anti-GATA-3 antibody.
Eluted complexes were then introduced into a second round of ChIP
using either anti-KDM4B or isotype control antibodies, and resultant
DNA was analysed by quantitative PCR using primers to Pro A, Enh1
and Enh2 regions. Data are the average of three independent experi-
ments± standard error.
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KDM4B depletion elevates H3K9me3 marks and reduces
GATA-3 binding to the ER gene
The binding of KDM4B to both enhancer and promoter
elements suggest it may have a role in modifying the chro-
matin landscape at these sites to facilitate GATA-3-
mediated transcription of the ER gene. To address this,
we ﬁrstly performed ChIP experiments using an anti-
histone H3K9me3 antibody in T47D cells transfected
with and without siKDM4B (C) oligonucleotides and
assessed ﬂux to this repressive mark in response to
10 nM E2 at Pro A, Enh1 and Enh2 loci. As shown in
Figure 5A (white bars), a marked decrease in H3K9me3
was observed in response to 45-min estrogen treatment
consistent with transcriptional activation. In cells
depleted of KDM4B, however, no decrease in H3K9me3
marks was observed in response to hormone stimulation
consistent with reduced ER expression. Moreover, consist-
ent with effects of KDM4B knock-down on basal ER
mRNA expression (Figure 2 and Supplementary Figure
S6), enrichment of H3K9me3 was increased at both
Enh1 and Enh2 regions in the absence of hormone on
KDM4B knock-down, conﬁrming a role for KDM4B as
a regulator of ER expression independently of the receptor
(Figure 5A, black bars). We also investigated the effect of
KDM4B depletion on H3K9 methylation of the ER gene
cis-regulatory elements in the EI-MCF-7 cell line. In
contrast to the consistent estrogen-dependent reduction
in H3K9me3 marks at Pro A, Enh1 and Enh2 in T47D
cells, only Enh1 and Enh2 loci demonstrated a reduction
in repressive methylation marks on estrogen stimula-
tion that was attenuated on KDM4B knock-down
(Supplementary Figure S16). Intriguingly, contrary to
data presented in Figure 2A, demonstrating a dependency
on KDM4B for ER expression in EI-MCF-7 cells, basal
H3K9me3 was markedly reduced on KDM4B depletion at
both Enh1 and Enh2 elements (Supplementary Figure
S16), suggesting there may be a partial uncoupling of
the repressive methylation mark and its effect on tran-
scriptional output of the ER gene in long-term steroid-
depleted conditions.
We next assessed the effect of KDM4B knock-down on
GATA-3 association at the promoter and enhancer
elements of the ER gene by ChIP in T47D cells. Given
that our experiments demonstrate constitutive GATA-3
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Figure 5. KDM4B regulates H3K9 methylation and GATA-3 binding at the ER gene promoter and enhancers. T47D cells were transfected with Scr
control or KDM4B (siKDM4B) siRNAs in steroid-depleted media for 48 h and treated with 10 nM E2 for 45min before ChIP analysis using anti-
H3K9me3 (A) or -GATA-3 antibodies (B). Resultant DNA was analysed by quantitative PCR using primers to Pro A, Enh1 and Enh2 regions, and
data shown are the average of three independent experiments± standard error (* denotes P< 0.05). (C) T47D cells grown in serum-containing media
were transfected with Scr control or siKDM4B siRNAs for 48 h before chromatin fractionation. Resultant lysates were subject to western blot
analysis using anti-GATA-3 and -histone H3 antibodies. Input samples were run alongside to demonstrate depleted KDM4B levels in response to
siRNA transfection. (D) MCF-7 and T47D cells were co-transfected with siRNAs (Scr or siKDM4B) and mammalian expression vectors (CS-
KDM4B or empty vector control) for 48 h in serum-containing media before RNA extraction and ER mRNA expression proﬁling by quantitative
PCR. Data are the average of three experiments performed±standard error (*P< 0.05). Parallel experiments were harvested in SDS-samples buffer
and subject to western blot analysis using anti-KDM4B and a-Tubulin antibodies.
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binding at Pro A, Enh1 and Enh2 loci (Figure 4B, middle
panel), we conducted ChIP experiments in the absence of
estrogen. At each of the cis-regulatory elements of the ER
gene, we observed that GATA-3 association is reduced by
50% in cells depleted of KDM4B, indicating an import-
ant role for KDM4B in facilitating GATA-3 binding
(Figure 5B). Reduced GATA-3 chromatin association
was not a consequence of reduced cellular GATA-3
protein levels as shown by western blot analysis of
lysates from MCF-7 and T47D cells subject to KDM4B
knock-down (Supplementary Figure S17). Moreover,
chromatin fractionation experiments [as described in
(25)] demonstrated that global GATA-3 chromatin
association is not attenuated on KDM4B depletion
(Figure 5C), implying that loss of GATA-3 from the ER
promoter and enhancer loci is a consequence of localized
chromatin remodelling and not a genome-wide
phenomenon.
To further provide evidence for KDM4B regulating ER
gene transcription, we performed RNAi-rescue experiments
in which MCF-7 and T47D were transiently transfected
with siKDM4B (C) together with either a KDM4B
cDNA resistant to siRNA-mediated depletion, termed
CS-KDM4B (see ‘Materials and Methods’ section) or
empty vector control. As expected, KDM4B knock-
down reduced ER expression in both BCa cell lines
(Figure 5D, black bars), albeit less in MCF-7 cells
compared with data presented in Figure 2A that may
reﬂect differences in the transfection procedure. In
contrast, overexpression of CS-KDM4B had minor effect
on ER mRNA levels in the presence of Scr siRNA control
(Figure 5D, compare lanes 1 and 2). However, ectopic ex-
pression of CS-KDM4B in cells depleted of the
demethylase was able to fully rescue receptor expression
in MCF-7 cells and by >50% in T47D cells, indicating a
genuine role for KDM4B in controlling transcription of the
ER gene (Figure 5D, compare lanes 2 and 4).
KDM4B interacts with and regulates FOXA1 expression
The importance of the pioneer factor FOXA1 in
regulating ER-mediated transcription is underscored by
the high proportion of receptor–target gene enhancer
elements containing FOXA1-binding forkhead motifs
and the requirement for deposition of FOXA1 at these
regions to facilitate active ER recruitment (25,28,29).
Our current understanding of selective FOXA1–chroma-
tin association is limited, but evidence suggests that
regions depleted of H3K9me2 and enriched for
H3K4me2 demarcate binding loci for this pioneer factor
(25). Given that KDM4B is a regulator of ER activity and
demethylates H3K9me3, we hypothesized that KDM4B
may regulate the discriminate deposition of FOXA1 and
hence participate in the global control of receptor
signalling. To this end, we ﬁrstly examined if FOXA1
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Figure 6. KDM4B interacts with and regulates expression of FOXA1. (A). MCF-7 cells grown in serum-containing media were subject to IP using
either anti-KDM4B or isotype control antibodies and resultant samples analysed by western blot analysis using FOXA1 and KDM4B immuno-
globulins (left panel). MCF-7 cells were also transiently transfected with or without KDM4B mammalian expression vectors for 48 h before IP using
an anti-FOXA1 antibody (right panel). Samples were analysed as before. (B) MCF-7 cells were transiently transfected with either Scr or KDM4B
(siKDM4B) siRNAs in serum-containing media for 48 h before ChIP analysis using anti-FOXA1 or isotype control antibodies. Data are the mean of
three independent experiments analysing FOXA1 recruitment to the pS2 gene promoter ERE. (C) T47D cells were transiently transfected with either
Scr or KDM4B (siKDM4B) siRNAs in serum-containing media for 48 h before chromatin fractionation and western blot analysis using anti-FOXA1
and a-Tubulin antibodies. (D) MCF-7 cells were transiently transfected with either Scr control or KDM4B (siKDM4B) siRNAs in steroid-depleted
media for 40 h before 10 nM estrogen treatment for 8 h. RNA was extracted from samples, and resultant cDNA was used in quantitative PCR to
assess FOXA1 expression levels (left panel). Parallel experiments were performed as described above and samples lysed in SDS-sample buffer before
western blot analysis using FOXA1, KDM4B and a-Tubulin antibodies (right panel).
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and KDM4B interacted by IP using an anti-KDM4B
antibody in MCF-7 cells. As shown in Figure 6A (left
panel), FOXA1 is present in KDM4B immunopre-
cipitates, but not in the isotype antibody control.
Performing the reciprocal experiment, we demonstrated
successful KDM4B co-IP from a FOXA1
immunocomplex in MCF-7 cells ectopically expressing
KDM4B (Figure 6A, right panel), indicating that the
proteins are in complex and could function together.
To address the role of KDM4B in regulating FOXA1
chromatin association, we performed ChIP using an anti-
FOXA1 antibody in MCF-7 cells depleted of KDM4B
and assessed binding of FOXA1 to the pS2 gene
enhancer. In cells transfected with Scr siRNA, we
detected 5-fold enrichment of FOXA1 binding over
isotype antibody control that was markedly reduced on
knock-down of the demethylase (Figure 6B). Using chro-
matin fractionation, we further showed that depletion of
KDM4B robustly reduced global binding of FOXA1 to
chromatin (Figure 6C). Importantly, however, assessment
of FOXA1 levels in MCF-7 cells depleted of KDM4B
demonstrated reduced expression of the pioneer factor in
the presence and absence of estrogen that was a direct
consequence of reduced mRNA expression (Figure 6D,
left panel) and not an effect on protein stability as
measured by cycloheximide time-course experiments
(Supplementary Figure S18).
To provide additional evidence that KDM4B was a regu-
lator of basal and estrogen-induced FOXA1 expression, we
showed that the demethylase was associated at three
upstream elements of the FOXA1 gene (Supplementary
Figure S19A) in the absence of estrogen and was reduced
on hormonal stimulation (Supplementary Figure S19B),
suggesting an important role for KDM4B in priming
FOXA1 transcription. Importantly, we found that repres-
sive H3K9me3 marks at these loci were reduced in response
to estrogen, but not in MCF-7 cells depleted of KDM4B,
implicating the enzyme in controlling expression of FOXA1
in both basal and estrogenic conditions (Supplementary
Figure S19C).
Given the interplay between GATA-3, ER, FOA1 and
KDM4B, we lastly wanted to establish if FOXA1 was
recruited to ER gene Pro A, Enh1 and Enh2 cis-regulatory
elements, as this could provide an additional level of
KDM4B-mediated regulation of the entire ER signalling
network. As shown in Supplementary Figure S20, we ﬁnd
that FOXA1 is recruited to the ER promoter and
enhancer elements in response to 45-min estrogen stimu-
lation that is markedly reduced by 180-min treatment,
suggesting FOXA1 has a potential role in regulating
expression of the receptor.
Together, the data suggest that KDM4B regulates ER
activity at multiple levels, including controlling ER ex-
pression and activity, and expression of FOXA1, a
critical component of the receptor signalling cascade.
DISCUSSION
The expanding repertoire of co-regulator and pioneer
factor proteins required for ER activity identiﬁed over
the past decade has provided an indication of the mech-
anistic complexity required for acute transcriptional
control of the receptor. Importantly, deregulated activ-
ity of several co-regulator proteins has been postulated
to facilitate the transition from hormone-naı¨ve to endo-
crine-therapy-resistant BCa (3), suggesting future
therapies for breast malignancy may target additional
components of the ER signalling cascade.
One such ER co-regulator, the HDM enzyme KDM4B,
has been shown in two previous studies to be a requisite
for transcriptional activation of several receptor-target
genes by demethylating repressive histone H3 lysine 9
tri-/di-methyl marks at gene promoter and enhancer
elements (14,15). In the present study, we have conﬁrmed
that KDM4B is a regulator of the ER signalling cascade,
but has challenged the concept that it is a direct ER co-
activator working exclusively to enhance transcription of
receptor–target genes. Instead, our data demonstrates that
KDM4B is a key regulator of ER gene transcription and
FOXA1 expression that together control the estrogen-de-
pendent phenotype of a high proportion of BCa cell lines
and primary tumours. Hence, KDM4B-depletion experi-
ments demonstrating reduced pS2 and GREB1 expression,
as well as attenuated proliferation in BCa cell lines
[(14,15), Supplementary Figures S1, S6, S9, S11 and
Figure 2], is likely a consequence of down-regulated ER
and FOXA1 levels that ultimately abrogates the global
receptor signalling network. Critically, one important
issue raised by our experiments is the discrepancy
between the reporting of ER protein levels on KDM4B
depletion by ourselves and the two previously published
studies (14,15). Using a total of four siRNAs, including
one used in the Shi et al. study (14), we have demonstrated
in multiple BCa cell lines grown in both steroid-containing
and -depleted conditions that reduced ER mRNA expres-
sion is a consistent phenotype of KDM4B knock-down.
Importantly, the Shi et al. study demonstrates KDM4B
association to the upstream regulatory elements of the ER
gene (14), consistent with our ﬁndings in Figure 4, sug-
gesting it is a genuine regulator of receptor expression.
Although difﬁcult to conclude, the differences may have
arisen through subtle variation in experimental param-
eters or detection that may occlude the identiﬁcation of
changes to ER levels in the aforementioned study (14).
GATA-3 is a well-characterized regulator of ER expres-
sion (17), but how it functions to directly control tran-
scription is not well deﬁned. Given the complex nature
of ER gene regulation, as evidenced by both GATA-3
and ER association to cis-regulatory elements of this
gene [(17), Figure 4], it was important to examine the con-
tribution of KDM4B to GATA-3–mediated receptor ex-
pression independently of the chromatin-bound ER. Our
data provide evidence that GATA-3 is a KDM4B-inter-
acting protein, adding to the growing list of transcrip-
tional regulators already shown to associate with this
demethylase, including components of the SWI/SNF-B
(15) and MLL2 (14) complexes. Furthermore, re-ChIP ex-
periments (Figure 4C) and KDM4B depletion studies
(Figure 5) indicate that the GATA-3–KDM4B interaction
is evident on enhancer and promoter elements of the ER
gene, in both basal and estrogen-stimulated conditions,
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and that KDM4B is required to reduce H3K9me3 levels at
these loci permitting GATA-3 binding and subsequent up-
regulation of receptor expression. Importantly, experi-
ments conducted in the absence of estrogen or in the
presence of Tamoxifen or the SERD fulvestrant
demonstrated that KDM4B depletion effectively down-
regulated basal ER expression, indicating that the
enzyme was functioning via GATA-3, and independently
of the receptor, to facilitate ER gene transcription
(Supplementary Figures S6, S14 and S15). This concept
is further supported by luciferase reporter experiments
demonstrating KDM4B-mediated co-activation of
GATA-3 transcriptional activity on the ER gene Enh2
promoter element (Supplementary Figure S13), although
this was not evident on the Enh1 element, which may be a
consequence of a non-physiological assay using cis-regu-
latory elements in isolation. Importantly, our data
describe a novel role for KDM4B as a co-regulator of
GATA-3 on the ER gene. Whether KDM4B functions
as a global regulator of GATA-3 remains to be addressed,
but given that GATA-3 acts as a pioneer factor for a
subset of ER-target genes (30) may suggest that it plays
an important role in controlling the chromatin deposition
and/or function of the transcription factor within the
receptor signalling cascade.
To further investigate the role of KDM4B in the ER
signalling cascade, we addressed the potential role of the
enzyme in controlling the function of the pioneer factor
FOXA1. Deposition of FOXA1 into enhancer elements
neighbouring ER-target genes is largely indispensable for
estrogen-dependent transcription (25,31), but how this
process is controlled remains ill-deﬁned. ChIP-
sequencing–based experiments have indicated FOXA1 en-
richment at regions of chromatin enriched for H3K4me2
and depleted of H3K9me2 marks (31), suggesting a poten-
tial role for H3K9 demethylase enzymes in the potenti-
ation of FOXA1–chromatin association. To this end, we
undertook KDM4B-depletion studies to address if this
impacted on focal and global association of the pioneer
factor using respective ChIP and chromatin fractionation
experiments. Unfortunately, these studies were hindered
by the intriguing ﬁnding that FOXA1 expression was
markedly reduced in response to KDM4B knock-down,
indicating that although we are unable to examine the
function of the enzyme in controlling FOXA1 chromatin
deposition, we have identiﬁed an additional component of
the ER signalling cascade that is transcriptionally
regulated by KDM4B. FOXA1 has previously been
shown to be directly up-regulated in MCF-7 cells by
estrogen treatment, suggesting it is a direct ER-target
gene (32). Therefore, reduced FOXA1 levels in response
to KDM4B depletion (Figure 6) may simply be a conse-
quence of down-regulated ER protein levels. However,
given that this effect was evident in conditions where the
ER was inactive does suggest that additional factors may
be co-operating with KDM4B to regulate FOXA1 tran-
scription. ChIP experiments demonstrated direct KDM4B
association upstream of the FOXA1 gene and depletion of
the demethylase attenuated removal of repressive
H3K9me3 marks required for estrogen-dependent
FOXA1 expression (Supplementary Figure S19).
Intriguingly, the three cis-regulatory elements upstream
of the FOXA1 gene that showed KDM4B association
are enriched for GATA-3-binding sites, suggesting that
interplay between these two proteins may, again,
regulate transcription of an important regulator of the
ER signalling cascade. To add further complexity to the
interplay between KDM4B and components of the ER
signalling system, we also showed that FOXA1 was re-
cruited to the ER gene promoter and enhancers in
response to hormone stimulation (Supplementary Figure
S20), suggesting that the effect of KDM4B knock-down
on ER expression may be a consequence of a combination
of lower FOXA1 levels and attenuated recruitment of
GATA-3 to upstream regulatory elements of the ER
gene. Future studies using KDM4B overexpression
model systems may provide a more suitable background
for examining the role of enhancer demethylation by this
enzyme to regulate FOXA1–chromatin association.
The development of therapeutic agents to target many
of the characterized epigenetic enzymes, so-called ‘epi-in-
hibitors’, provides several opportunities for the treatment
of a plethora of diseases including cancer. Given the role
of several HDM enzymes in the propagation and progres-
sion of malignancy and neurological disorders (33), there
is substantial interest in the development of demethylase
inhibitors (HDMi) for the treatment of these diseases.
Importantly, this work and ﬁndings from a number of
translational studies (14,15,16) suggest KDM4B is a real-
istic therapeutic target for estrogen-dependent BCa treat-
ment; KDM4B is overexpressed in aggressive disease,
depletion of the enzyme reduces BCa cell growth in vitro
and in vivo and enhances BCa cell cytotoxicity
(Supplementary Figure S11) without affecting growth of
ER negative cell lines (14,15). Although at present there
are no indications of recurrent KDM4B mutations in
BCa, or indeed other cancer types, acquisition of
activating mutations in KDM4B or KDM4B gene
silencing by methylation may be a contributory factor in
the persistence or loss of ER expression during BCa de-
velopment and response to treatment. This is an important
avenue that needs further exploration. Importantly,
KDM4B knockout animals are phenotypically normal
(15), indicating that the enzyme is not a general regulator
of cellular proliferation and aberrant expression in BCa is
acquired on cellular transformation, suggesting targeting
KDM4B is potentially tumour speciﬁc. KDM4 family
members, including KDM4A-E, demonstrate >98%
sequence identity within the catalytic JmjC domain, high-
lighting selective targeting of the enzyme may not be
achievable. However, the recent demonstration that
KDM4C is a target gene and co-regulator of hypoxia-in-
ducible factor 1, and demonstrates elevated expression in
invasive BCa and is required for lung metastasis in vivo
(34), suggests that a pan-KDM4 family inhibitor may be
beneﬁcial to patients who have failed neo-adjuvant
therapy but retain expression of the ER.
In summary, our data demonstrate that KDM4B is a
master regulator of the ER signalling cascade by
controlling ER and FOXA1 expression and that these
gene targets are likely to be a major contributing factor
to the KDM4B-knock-down phenotype seen in BCa cell
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lines in vitro and in vivo (14,15). Ultimately, are ﬁndings
support the development of agents to down-regulate
KDM4B activity for BCa treatment and have identiﬁed,
in the form of the ER and FOXA1, two potential bio-
markers for drug development programmes.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online:
Supplementary Tables 1 and 2 and Supplementary
Figures 1–20.
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